Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer
Omics International publishes 304 Open Access Articles in 13 International Journals it has 32 Upcoming Conferences and 15 Previous Conferences with 581 Conference Proceedings and 92 National symposiums
Rigidity or stiff or inflexible muscles is one of the main symptoms of Parkinson's, alongside tremor and slowness of movement. In Parkinson’s rigidity is often most noticeable when you move a joint through a circular movement. The movement often feels as if the joint is moving through a number of cogs, known as ‘cogwheel rigidity’. Some people also experience a constant resistance to motion throughout the entire range of movement, known as 'lead pipe rigidity'. Rigidity can stop muscles from stretching and relaxing. It can causes, Stiff muscles, Inflexible muscles, Pain and muscle cramps, Fixed ‘mask-like’ facial expression, Inability to swing arm or arms when walking, Difficulties getting out of chairs, turning over in bed and turning around, Difficulties with fine movements such as writing or doing up buttons, Postural changel and Fatigue.
OMICS International through its Open access initiatives is committed to make genuine and reliable contributions to the scientific community by publishing research work and conference paper related to such disorders. It is known that OMICS Group hosts over 700 edge peer reviewed Open Access Journals and organizes over more than 1000 Global Events annually. Its publishing group journals have over 5 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 75000+ eminent personalities that ensure a quality and quick review process checker.
Rigidity is a progressive, degenerative neurological movement disorder that affects approximately 6.3 million people worldwide. Although it typically develops after the age of 65, about 15% of people with the condition develop "young-onset" Parkinson's disease before reaching age 50. The incidence of the disease rises steeply with age; from 17.4 in 100,000 person years between 50 and 59 years of age to 93.1 in 100,000 person years between 70 and 79 years.It is estimated that 1 in every 10,000 Americans has Rigidity or movement disorder and more than 250,000 others are at risk of having inherited it from a parent. According to available statistics, 1.2 million people in Europe have Parkinson’s, which approximates to 260,000 in Germany ; 200,000 in Italy; 150,000 in Spain ; 120,000 in UK; 117,000 in France. This equates to a rate of more than 1 per 1000 people in Europe, making it the second most common neurodegenerative disorder. Approximately 80,000 Australians develops after the age of 65, about 15% of people with the condition develop "young-onset" Parkinson's disease before reaching age 50.
The global epilepsy market was valued at an estimated $4.2 billion in 2012. The expected market growth is to $5.35 billion by 2022, with more than 50% of sales coming from the US. An epileptic seizure is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action. The global deep brain stimulators market was valued at USD 529.5 million in 2013 and is expected to grow at a CAGR of 17.1% during the forecast period. However, high costs associated with these devices, chances of electrode infection and availability of alternate therapies are some factors expected to impede market growth.
This page will be updated regularly.
This page was last updated on August 19, 2022